Physician profile
Landon Colling
NPI 1952517187
$1,173.33
in general payments reported to CMS, 2019-2025
14 companies · $94.71 in 2025
The $94.71 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148 · 2020: $66.93 · 2021: $112 · 2022: $132 · 2023: $321 · 2024: $298 · 2025: $94.71.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $714.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $714.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $385.07 | 2019-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $196.35 | 2022-2024 | Vabysmo |
| Bausch & Lomb Americas INC. | $153.80 | 2023-2024 | Scoutpro Osmolarity System, Vyzulta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $107.23 | 2019-2021 | |
| Abbvie INC. | $69.01 | 2022-2024 | Durysta |
| Novartis Pharmaceuticals Corporation | $57.49 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $38.08 | 2019 | |
| Astellas Pharma US INC | $34.44 | 2025 | Izervay |
| Tarsus Pharmaceuticals, INC. | $30.92 | 2024 | Xdemvy |
| Allergan, INC. | $25.04 | 2021 | |
| Apellis Pharmaceuticals, INC. | $21.87 | 2023 | Syfovre |
| Kala Pharmaceuticals, INC. | $19.13 | 2021 | |
| Dompe US, INC. | $18.04 | 2024 | Oxervate |
| Horizon Therapeutics Plc | $16.86 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Landon Colling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.